경구 당뇨병 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Oral Anti-Diabetic Drug Market size is expected to reach USD 68.55 Billion in 2034 from USD 46.97 Billion (2025) growing at a CAGR of 4.29% during 2026-2034.

The oral anti-diabetic drug market expanded substantially with the rising global prevalence of type 2 diabetes, driven by ageing populations, urbanization, and lifestyle changes. Key therapeutic classes-metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and newer fixed-dose combinations-have broadened treatment options. Market growth was supported by improved diagnosis rates, guideline updates favoring combination therapy, and the shift to chronic outpatient management. Generic penetration for older molecules kept unit volumes high while branded novel agents captured premium shares.

Drivers of growth include increasing diabetes prevalence, greater screening and diagnosis, and clinician preference for drugs with cardiovascular and renal outcome benefits. Payer coverage expansions and the availability of affordable generics have widened patient access in many regions. Pharmaceutical R&D focusing on agents with multifactorial benefits (weight loss, cardioprotection) along with fixed-dose combination pills has encouraged adherence and simplified regimens, lifting market value despite pricing pressures in some markets.

Looking forward, the market will likely evolve toward personalized therapy incorporating comorbidity profiles and cost-effectiveness. Biosensor- and digital-integrated care models may pair oral therapies with monitoring to improve outcomes. Patent expirations of some branded agents will increase generic competition, while novel small molecules and combination therapies could capture new segments. Market growth will hinge on balancing affordability, long-term outcome data, and healthcare system capacity to manage expanding patient numbers.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Biguanides
• Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors
• Sodium-Glucose Transport Protein-2 (Sglt-2) Inhibitors
• Sulfonylureas
• Thiazolidinediones
• Meglitinides
• Alpha-Glucosidase Inhibitors
• Other Drug Classes

By Disease Type

• Type 2 Diabetes
• Type 1 Diabetes

By Medication Type

• Branded
• Generic

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Glenmark Pharmaceuticals, Johnson Johnson Janssen Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda Pharmaceuticals

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Biguanides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Sodium-Glucose Transport Protein-2 (Sglt-2) Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Sulfonylureas Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Thiazolidinediones Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Meglitinides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Alpha-Glucosidase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Type
• 5.2. Type 2 Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Type 1 Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY MEDICATION TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Medication Type
• 6.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Generic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Disease Type
  • 8.2.3 By Medication Type
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Disease Type
  • 8.3.3 By Medication Type
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Disease Type
  • 8.4.3 By Medication Type
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Disease Type
  • 8.5.3 By Medication Type
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Disease Type
  • 8.6.3 By Medication Type
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ORAL ANTI-DIABETIC DRUG INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Astellas Pharma
  • 10.2.2 AstraZeneca
  • 10.2.3 Bayer
  • 10.2.4 Boehringer Ingelheim
  • 10.2.5 Bristol Myers Squibb
  • 10.2.6 Eli Lilly And Company
  • 10.2.7 Glenmark Pharmaceuticals
  • 10.2.8 Johnson & Johnson (Janssen Pharmaceuticals)
  • 10.2.9 Merck
  • 10.2.10 Novartis
  • 10.2.11 Novo Nordisk
  • 10.2.12 Pfizer
  • 10.2.13 Sanofi
  • 10.2.14 Takeda Pharmaceuticals